MAPK3 and melanoma: As reported for other cell systems28, treating NRASQ61 mutant melanoma cells with 2-DG not only induced ERK1/2 phosphorylation but also PFKFB2 phosphorylation, which was abolished upon sorafenib treatment (Fig. 8a).